January 15, 2020

Optometrists begin their journey to offer CooperVision’s innovative myopia management approach to parents and children across the nation

SAN RAMON, Calif., January 15, 2020—As CooperVision prepares for the March 2020 launch of MiSight® 1 day contact lenses in the U.S., the company kicked off the new year by announcing details on its comprehensive myopia management approach this week. An initial group of the nation’s eye care professionals (ECPs) gathered in Miami, Florida on January 7 – 8 to learn about the Brilliant Futures Myopia Management Program and prepare to prescribe the MiSight® 1 day lens to patients.

The CooperVision MiSight® 1 day lens is the first and only product1 U.S. Food and Drug Administration approved for slowing the progression of myopia when initially prescribed for children 8-12 years old*.

The Brilliant Futures Myopia Management Program seeks to create a new standard of care for children with myopia. It provides inclusive practice, child and parent support to create the optimal environment for compliance, satisfaction, clinical outcomes and long-term loyalty, all via a comprehensive management program featuring MiSight® 1 day daily disposable contact lenses.

“We believe success in addressing the rising severity and prevalence of myopia progression involves commitments from the parent, the child and the practitioner. This is why we are taking a new approach to partnering with eye care practitioners to help them achieve the best possible outcomes,” said Michele Andrews, OD, Senior Director of North America Professional & Academic Affairs at CooperVision.

The program features:

  • Transparent, defined protocol for care, meaning the patient is aware of everything included in the program (including services and lenses) while promoting confidence and efficiency for ECPs.
  • Free product shipping and returns, creating no-hassle product availability for the patient, thereby enabling better compliance for the wearer and removing the guesswork from developing and marketing a supply strategy for the ECP.
  • An interactive mobile app to keep patients engaged with the practice and their program of care, providing convenient access to myopia management information, lens handling instructions and videos, appointment scheduling and reminders, product ordering and more.

The inaugural launch event was held for an initial group of ECPs interested in offering the comprehensive myopia management approach in their practices, in advance of the broader March roll-out. During the event, CooperVision and the attending ECPs recognized the historic FDA approval1 of MiSight® 1 day contact lenses. Excitement grew as CooperVision executives shared details about the Brilliant Futures™ Myopia Management Program and the company’s vision to partner with and support optometrists who bring the program into their offices and to their patients this spring.

Attendees also heard from ECPs from across the globe who currently prescribe MiSight® 1 day lenses in their practices. Indie Grewal, OD, the largest MiSight® 1 day contact lens prescriber in the United Kingdom, shared his experience with the group. He talked about how he approaches educating parents about myopia and why a myopia management program that incorporates MiSight® 1 day can be beneficial to patients and the practice. 

The ECPs were treated to a robust day of education delivered by global experts in myopia, including Dr. Mark Bullimore, Paul Chamberlain, Debbie Jones, Dr. Nicola Logan and Sarah Morgan. The day included a mix of didactic and hands-on learning. Topics included an overview of the global myopia epidemic, MiSight® 1 day clinical research details, and an in-depth look at all elements of the Brilliant Futures Myopia Management Program.

“The excitement and interest from ECPs at the event affirms for us that the profession is ready and waiting for a new standard of care in myopia management, and we believe we can provide that with Brilliant Futures Myopia Management Program and MiSight® 1 day lenses,” said Dr. Andrews.

ECPs who gain certification to implement Brilliant Futures Myopia Management Program in their practice will receive extensive support from CooperVision, including:

  • Ongoing ECP education. ECPs will have online access to the latest information about myopia management, insights on parent and patient beliefs and behaviors, and how those apply to prescribing MiSight® 1 day.
  • Specialist support. Every certified provider will be connected with a specialist in both the clinical and practice integration elements of the comprehensive program, allowing one-to-one conversations tailored to specific practice opportunities and needs.
  • Myopia management toolbox. Practices will receive patient and parent education tools, staff training tools, practice integration support and community outreach and engagement resources.

“I’m a firm believer that effective communication leads to better outcomes through increased compliance—especially when outlining a myopia diagnosis and treatment plan to my pediatric patients and their parents,” said Roxanne Achong-Coan, OD, FAAO, FIAOMC, FSLS, at Coan Eye Care. “CooperVision’s Brilliant Futures Myopia Management Program has several great education tools for me and my staff to use. It will be a great asset to my practice, and I am looking forward to offering this program to my patients.”

Practices who are interested in learning more about the Brilliant Futures Myopia Management Program featuring MiSight® 1 day can visit coopervision.com/practitioner/myopia-management.

# # #

MiSight® 1 day contact lenses are currently approved for sale in the United States, Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Italy, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® 1 day is not approved in Japan.

1 MiSight® (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of  myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75  to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

* When compared to the children in the control group wearing a single vision 1-day contact lens over a 3-year period. Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci 2019; 96:556-567.

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Jamie Palmeroni-Lavis, McDougall Communications
jamie@mcdougallpr.com or +1-585-434-2151